My fantasy solution, which I have posted once before, is that RCPI, with the agreement of their creditors, filed for Chapter 7 in Sept. 2016 to stop the hemoeraging of share issuance which was occuring under their failed lending agreement. Eventually, MYmd Pharmaceuticals, which was formed as a private company in 2014 and which was filing many patents for isomyosmine would reverse merge with RCPI which had petioned for and was transferred to Chapter 13 status. Upon completion of the merger MYMD would change the name of the company to MyMD Pharmaceuticals and retain the share status of RCPI, exchanging 10 shares of RCPI for 1 share of MyMD. This would leave MyMD Pharma with about 17 million shares outstanding, an ideal balance for a small biotec company with impressive potential. This would also retain as stockholders, investors like myself who had been on board with Star Scientific since before the infamous court case.
How likely that this is actually the case? Not very, but we long suffering RCPI stockholders have learned to live in hope that Jonnie R. Williams Sr. will finally be vidicated.
